Ridge Bio
United States
- Palo Alto, CA
- 10/09/2025
- Seed
- $25,000,000
Ridge Biotechnologies is pioneering AI-based enzyme and targeted drug design to power the next wave of precision therapeutics.
Led by a collection of established biotech entrepreneurs and faculty from top institutions, we use proprietary machine learning models informed by high-throughput cell-free experimentation for a wide range of applications in antibody-drug conjugates (ADCs), conditionally active prodrugs, in vivo CART therapies, targeted nucleic acid delivery, radiotherapies, and enzyme-based therapeutics.
Our current product lines include NativeLink enzymes that enable precision bioconjugation including construction of ADCs and Antibody-oligonucleotide conjugates, ProTrigger linkers that provide tissue and disease-specific activation and release of diverse payloads and prodrugs, and new classes of enzyme-based Catalytic Medicines.
We are focused on enabling our partners to build better drugs for patients.
- Industry Biotechnology Research
- Website https://ridgebio.com/
- LinkedIn https://www.linkedin.com/company/ridge-bio/
catalyx space | $5,400,000 | (Nov 4, 2025)
mimic(SWITZERLAND) | $160,000,000 | (Nov 4, 2025)
xMEMS | $21,000,000 | (Nov 4, 2025)
Zeeg | $1,265,935 | (Nov 4, 2025)
Cephia AI | $4,000,000 | (Nov 4, 2025)
Ornn | $5,700,000 | (Nov 4, 2025)
octonomy | $20,000,000 | (Nov 4, 2025)
Helex | $3,500,000 | (Nov 4, 2025)
Hullbot | $16,000,000 | (Nov 4, 2025)
Indomo | $25,000,000 | (Nov 4, 2025)
AUI™ (Augmented Intelligence) | $20,000,000 | (Nov 4, 2025)
Popai Health | $11,000,000 | (Nov 4, 2025)